David A. Siegel Plus Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.27 - $0.48 $189 - $336	-700 Reduced 2.13%	32,100 $9,000
Q4 2022 Feb 14, 2023	SELL	$0.3 - $8.4 $2,850 - $79,800	-9,500 Reduced 22.46%	32,800 $10,000
Q3 2022 Nov 14, 2022	SELL	$0.48 - $7.5 $3,408 - $53,250	-7,100 Reduced 14.37%	42,300 $19,000
Q2 2022 Aug 15, 2022	SELL	$0.46 - $1.02 $13,662 - $30,294	-29,700 Reduced 37.55%	49,400 $27,000
Q1 2022 May 16, 2022	SELL	$0.87 - $1.32 $160,950 - $244,200	-185,000 Reduced 70.05%	79,100 $79,000
Q4 2021 Feb 14, 2022	BUY	$1.03 - $1.94 $208,781 - $393,238	202,700 Added 330.13%	264,100 $277,000
Q3 2021 Nov 15, 2021	SELL	$1.83 - $2.46 $208,803 - $280,686	-114,100 Reduced 65.01%	61,400 $117,000
Q2 2021 Aug 16, 2021	BUY	$2.0 - $2.89 $228,600 - $330,327	114,300 Added 186.76%	175,500 $449,000
Q1 2021 May 17, 2021	BUY	$2.1 - $3.75 $76,230 - $136,125	36,300 Added 145.78%	61,200 $147,000
Q4 2020 Feb 16, 2021	BUY	$2.0 - $2.76 $49,800 - $68,724	24,900 New	24,900 $50,000

Ticker PSTV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,601,400
Market Cap $40M
Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, lep...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.